Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.

In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.

Zhitong FinanceFeb 13 22:11 ET

[Brokerage Focus] BOCOM INTL points to new opportunities in the medical Sector driven by AI technology, focusing on innovation related to AI and opportunities for valuation recovery.

Jingu Finance News | BOCOM INTL stated that multiple pharmaceutical companies have integrated DeepSeek, accelerating the implementation of AI + Medical Services. Many companies in the digital medical field, such as Yidu Technology, announced the integration of DeepSeek-R1 model, and Jiangsu Hengrui Pharmaceuticals and INNOVENT BIO also indicated that they will fully carry out DeepSeek application work. Moreover, the National Healthcare Security Administration has reiterated the reform of payment collection. The administration mentioned the achievements of the settlement reform in Jiangxi Province, where the payment collection cycle for medical supply companies has reduced from half a year to 30 days. The bank pointed out that AI large models empower digital medical services companies, showing significant potential in disease diagnosis/detection. At the same time,

Jinwu Financial NewsFeb 13 20:10 ET

HANSOH PHARMA (03692): Xin Yue (Inalimumab injection) new indications included in the priority review and approval process.

HANSOH PHARMA (03692) announced that on February 8, 2025, based on Xinyue.

Zhitong FinanceFeb 9 19:40 ET

The "DeepSeek Moment" of medicine, has China’s Innovative Drugs also reached it?

Over the past four years, China's share of Global large-scale pharmaceutical Trade has surged from 5% to 30%. From research and development innovation to international mergers and acquisitions, Chinese Innovative Drugs companies are reshaping the Global pharmaceutical innovation landscape.

wallstreetcnFeb 7 20:59 ET

Hansoh Pharmaceutical Group's (HKG:3692) Investors Will Be Pleased With Their Favorable 55% Return Over the Last Year

Simply Wall StJan 30 02:06 ET

BOCOM INTL: Expectations for the implementation of Class C medical insurance catalog have further increased this year, giving a "leading" rating to the mainland Pharmaceutical Industry.

A "leading" rating is given to the domestic pharmaceutical Industry, with a focus on Innovation and valuation recovery as the two main lines. The expectation for the implementation of the Category C medical insurance directory within the year has further increased, which is expected to support the establishment of a diversified payment mechanism for Innovative Drugs.

Zhitong FinanceJan 27 03:33 ET